DENT Neurologic Institute prepared to move forward with Alzheimer's drug despite controversy

DENT Neurologic Institute is ready to proceed with administering the newly-approved Alzheimer's drug aducanumab, also called Aduhelm, even as hospitals across the country announce they are not going to prescribe the drug due to concerns over its efficacy and questions about the FDA approval process.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting